BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/7/2017 8:24:12 AM | Browse: 778 | Download: 1588
 |
Received |
|
2016-10-11 08:29 |
|
Peer-Review Started |
|
2016-10-14 08:03 |
|
To Make the First Decision |
|
2016-11-10 08:40 |
|
Return for Revision |
|
2016-11-14 14:47 |
|
Revised |
|
2016-11-26 11:47 |
|
Second Decision |
|
2016-12-20 15:47 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2017-01-03 15:22 |
|
Articles in Press |
|
2017-01-03 15:22 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2017-01-09 11:13 |
|
Typeset the Manuscript |
|
2017-03-30 14:41 |
|
Publish the Manuscript Online |
|
2017-04-07 08:24 |
| ISSN |
2218-4333 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medical Laboratory Technology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Study of recombinant human interleukin-12 for treatment of complications after radiotherapy for tumor patients
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Na Guo, Wen-Qin Wang, Xiao-Jing Gong, Lei Gao, Li-Rong Yang, Wei-Na Yu, Hong-Yu Shen, Ling-Qin Wan, Xi-Feng Jia, Yi-Shan Wang and Yi Zhao |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dr. Yi-Shan Wang, Center for Tumor Treatment, People’s Liberation Army 107th Hospital, 7 Zhichu South Road, Yantai 264002, Shandong Province, China. wangyishan288@163.com |
| Key Words |
Recombinant human interleukin-12; Cancer prevention; Radiotherapy complications; Clinical research |
| Core Tip |
Recombinant human interleukin-12 (rhIL-12) is a new kind of biological agent secreted by Chinese hamster ovary cells. Study has shown that it has the advantage of promoting recovery of hematopoietic function, regulating the body’s immunity and inhibiting angiogenesis growth. At present, the research of rhIL-12 stays in the foundational realm and in animal experimentation. In our study, however, there were 100 patients with large or numerous tumors (more than two) and who received precision radiotherapy (Cyber knife or image-guided radiotherapy). The results showed that rhIL-12 can prevent radiation damage, improve hematopoietic function, regulate im¬munity, reduce the side effect of radiotherapy and im¬prove the quality of life of patients. |
| Publish Date |
2017-04-07 08:24 |
| Citation |
Guo N, Wang WQ, Gong XJ, Gao L, Yang LR, Yu WN, Shen HY, Wan LQ, Jia XF, Wang YS, Zhao Y. Study of recombinant human interleukin-12 for treatment of complications after radiotherapy for tumor patients. World J Clin Oncol 2017; 8(2): 158-167 |
| URL |
http://www.wjgnet.com/2218-4333/full/v8/i2/158.htm |
| DOI |
http://dx.doi.org/10.5306/wjco.v8.i2.158 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
